{"commentary":{"count":325,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":134,"youtube":104,"podcast":75,"x_video":12},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05382286\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ASCENT-04","nct_id":"NCT05382286","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ascent-04-nct05382286. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"ASCENT-04","arms":[{"description":"Participants will receive SG 10 mg/kg on Days 1 and 8 of 21-day cycles and pembrolizumab 200 mg on Day 1 of 21-day cycles\n\nPembrolizumab will be administered for a maximum of 35 cycles.","label":"Sacituzumab Govitecan-hziy (SG) + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants will receive pembrolizumab 200 mg on Day 1 of each 21-day cycle (maximum 35 cycles) plus TPC determined prior to randomization from 1 of the 3 allowed regimens:\n\n* Paclitaxel 90 mg/m\\^2 on Days 1, 8, and 15 of 28-day cycles\n* nab-Paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 of 28-day cycles\n* Gemcitabine 1000 mg/m\\^2 + carboplatin area under the curve (AUC) 2 on Days 1 and 8 of 21-day cycles","label":"Pembrolizumab + Treatment of Physician's Choice (TPC)","type":"ACTIVE_COMPARATOR"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2027-02","type":"ESTIMATED"},"conditions":["Triple Negative Breast Cancer","PD-L1 Positive"],"enrollment":{"count":443,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Sacituzumab Govitecan-hziy","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"nab-Paclitaxel","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"}],"last_update":"2025-09-18","lead_sponsor":"Gilead Sciences","official_title":"A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1","timeFrame":"Randomization up to approximately 33 months"}],"references":[{"citation":"Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim SB, Yam C, Rapoport B, Im SA, Pistilli B, Mchayleh W, Cescon DW, Watanabe J, Banuelas MAL, Freitas-Junior R, Salvador Bofill J, Afshari M, Gary D, Wang L, Lai C, Schmid P; ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators. Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. N Engl J Med. 2026 Jan 22;394(4):354-366. doi: 10.1056/NEJMoa2508959.","pmid":"41564397","type":"DERIVED"}],"start_date":{"date":"2022-07-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","url":"https://clinicaltrials.gov/study/NCT05382286"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ascent-04-nct05382286"}